ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Companies

Fujifilm to use stem cells to fight leukemia therapy complications

Company set to become Japan's first to bring iPS cells to clinical trials

TOKYO -- Fujifilm will apply for permission as soon as this fiscal year to run clinical trials on a treatment using a type of stem cell derived from adult tissue, aiming to become Japan's first company to test the cells for practical use in regenerative medicine.

The Fujifilm Holdings unit aims to start testing the therapy, aimed at patients with severe complications from leukemia treatment, in 2019, and hopes to win approval to manufacture and market the therapy in 2022. Preliminary discussions with oversight agencies are nearly complete.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more